Nisha I Parikh1, Mariana Gerschenson2, Kara Bennett3, Louie Mar M Gangcuangco3, Mary S Lopez2, Nehal N Mehta4, Martin P Playford4, Beau K Nakamoto5, Todd B Seto6, Dominic C Chow3, Cecilia M Shikuma3. 1. Hawaii Center for AIDS, Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA; Cardiovascular Division, Department of Medicine, University of California San Francisco, CA, USA. Electronic address: nparikh@medicine.uscf.edu. 2. Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA. 3. Hawaii Center for AIDS, Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA. 4. Section of Inflammation and Cardiometabolic Diseases, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. 5. Hawaii Center for AIDS, Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA; Department of Neurology, Straub Clinics and Hospital, Honolulu, HI, USA. 6. Cardiovascular Division, The Queens Medical Center, Honolulu, HI, USA.
Abstract
BACKGROUND: Association of lipoprotein particle size/number and HDL function with mitochondrial oxidative stress and function may underlie the excess cardiovascular (CVD) risk in HIV. METHODS AND RESULTS: Among HIV infected individuals on stable highly active antiretroviral therapy, we related standard and novel lipid measures [plasma total cholesterol, triglycerides, HDL-C, LDL-C, lipoprotein particle (-P) subclass size and number and HDL function (via cholesterol-efflux capacity)] with oxidative stress [peripheral blood mononuclear cell's mitochondrial-specific 8-oxo-deoxyguanine (8-oxo-dG)] and function markers [oxidative phosphorylation (OXPHOS) NADH dehydrogenase (Complex I) and cytochrome c oxidase (Complex IV) enzyme activities]. Multivariable-adjusted logistic and linear regression analyses were employed adjusting for age, gender, CD4 nadir, viral load, smoking, diabetes, HOMA-IR, hypertension and lipid medications. Among 150 HIV-infected persons (mean age 52 years, 12% women, median CD4 count 524 cell/mm3), low HDL-C and high total cholesterol/HDL-C ratio were related to PBMC 8-oxo-deoxyguanine (p = 0.01 and 0.02 respectively). Large HDL-P and HDL-P size were inversely related to PBMC 8-oxo-deoxyguanine (p = 0.04). Small LDL-P (p = 0.01) and total LDL-P (p = 0.01) were related to decreased OXPHOS Complex I activity. LDL-P was related to decreased OXPHOS Complex IV activity (p = 0.02). Cholesterol efflux capacity was associated with increased OXPHOS Complex IV activity. CONCLUSIONS: HDL concentration and particle size and number are related to decreased PBMC mitochondrial oxidative stress whereas HDL function is positively related to mitochondrial oxidative function. The association we find between atherogenic lipoprotein profile and increased oxidative stress and function suggests these pathways may be important in the pathogenesis of cardiometabolic disease in HIV disease.
BACKGROUND: Association of lipoprotein particle size/number and HDL function with mitochondrial oxidative stress and function may underlie the excess cardiovascular (CVD) risk in HIV. METHODS AND RESULTS: Among HIV infected individuals on stable highly active antiretroviral therapy, we related standard and novel lipid measures [plasma total cholesterol, triglycerides, HDL-C, LDL-C, lipoprotein particle (-P) subclass size and number and HDL function (via cholesterol-efflux capacity)] with oxidative stress [peripheral blood mononuclear cell's mitochondrial-specific 8-oxo-deoxyguanine (8-oxo-dG)] and function markers [oxidative phosphorylation (OXPHOS) NADH dehydrogenase (Complex I) and cytochrome c oxidase (Complex IV) enzyme activities]. Multivariable-adjusted logistic and linear regression analyses were employed adjusting for age, gender, CD4 nadir, viral load, smoking, diabetes, HOMA-IR, hypertension and lipid medications. Among 150 HIV-infectedpersons (mean age 52 years, 12% women, median CD4 count 524 cell/mm3), low HDL-C and high total cholesterol/HDL-C ratio were related to PBMC8-oxo-deoxyguanine (p = 0.01 and 0.02 respectively). Large HDL-P and HDL-P size were inversely related to PBMC8-oxo-deoxyguanine (p = 0.04). Small LDL-P (p = 0.01) and total LDL-P (p = 0.01) were related to decreased OXPHOS Complex I activity. LDL-P was related to decreased OXPHOS Complex IV activity (p = 0.02). Cholesterol efflux capacity was associated with increased OXPHOS Complex IV activity. CONCLUSIONS: HDL concentration and particle size and number are related to decreased PBMCmitochondrial oxidative stress whereas HDL function is positively related to mitochondrial oxidative function. The association we find between atherogenic lipoprotein profile and increased oxidative stress and function suggests these pathways may be important in the pathogenesis of cardiometabolic disease in HIV disease.
Authors: C Vigouroux; S Gharakhanian; Y Salhi; T H Nguyen; D Chevenne; J Capeau; W Rozenbaum Journal: Diabetes Metab Date: 1999-09 Impact factor: 6.041
Authors: Sekar Kathiresan; James D Otvos; Lisa M Sullivan; Michelle J Keyes; Ernst J Schaefer; Peter W F Wilson; Ralph B D'Agostino; Ramachandran S Vasan; Sander J Robins Journal: Circulation Date: 2005-12-27 Impact factor: 29.690
Authors: Daniel A Duprez; Lewis H Kuller; Russell Tracy; James Otvos; David A Cooper; Jennifer Hoy; Jacqueline Neuhaus; Nicholas I Paton; Nina Friis-Moller; Fiona Lampe; Angelike P Liappis; James D Neaton Journal: Atherosclerosis Date: 2009-05-13 Impact factor: 5.162
Authors: Scott W Ballinger; Cam Patterson; Cynthia A Knight-Lozano; David L Burow; Caryl A Conklin; Zhaoyong Hu; Johannes Reuf; Chris Horaist; Russell Lebovitz; Glenn C Hunter; Ken McIntyre; Marschall S Runge Journal: Circulation Date: 2002-07-30 Impact factor: 29.690
Authors: Samia Mora; James D Otvos; Nader Rifai; Robert S Rosenson; Julie E Buring; Paul M Ridker Journal: Circulation Date: 2009-02-09 Impact factor: 29.690
Authors: Lewis Kuller; Alice Arnold; Russell Tracy; James Otvos; Greg Burke; Bruce Psaty; David Siscovick; David S Freedman; Richard Kronmal Journal: Arterioscler Thromb Vasc Biol Date: 2002-07-01 Impact factor: 8.311
Authors: Mariana Gerschenson; Courtney Kim; Baiba Berzins; Babafemi Taiwo; Daniel E Libutti; Julia Choi; Diana Chen; Jill Weinstein; Jessica Shore; Barbara da Silva; Elizabeth Belsey; Grace A McComsey; Robert L Murphy Journal: J Antimicrob Chemother Date: 2009-03-25 Impact factor: 5.758
Authors: Mary K Swinton; Aliyah Carson; Francesca Telese; Ana B Sanchez; Benchawanna Soontornniyomkij; Leila Rad; Isabella Batki; Brandi Quintanilla; Josué Pérez-Santiago; Cristian L Achim; Scott Letendre; Ronald J Ellis; Igor Grant; Anne N Murphy; Jerel Adam Fields Journal: Neurobiol Dis Date: 2019-06-22 Impact factor: 5.996
Authors: Marla J Berry; Joshua Astern; Frederick Bellinger; Christopher Brampton; Rebecca Cann; Mariana Gerschenson; David Haymer; Nicholas G James; David M Jameson; Olivier LeSaux; Peter R Hoffmann; Robert Nichols; Matthew Pitts; Lucia Seale; Steven Seifried; Alexander J Stokes; Cedomir Todorovic Journal: Hawaii J Med Public Health Date: 2015-04
Authors: Jerel Adam Fields; Elisabeth Serger; Sofia Campos; Ajit S Divakaruni; Changyoun Kim; Kendall Smith; Margarita Trejo; Anthony Adame; Brian Spencer; Edward Rockenstein; Anne N Murphy; Ronald J Ellis; Scott Letendre; Igor Grant; Eliezer Masliah Journal: Neurobiol Dis Date: 2015-11-22 Impact factor: 5.996
Authors: Theodoros Kelesidis; Michael N Oda; Mark S Borja; Yumin Yee; Kit F Ng; Diana Huynh; David Elashoff; Judith S Currier Journal: J Acquir Immune Defic Syndr Date: 2017-07-01 Impact factor: 3.771
Authors: Joanne LaFleur; Adam P Bress; Lisa Rosenblatt; Jacob Crook; Paul E Sax; Joel Myers; Corey Ritchings Journal: AIDS Date: 2017-09-24 Impact factor: 4.177